About: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1996 (uk) article scientifique publié en 1996 (fr) im Februar 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 1996 (ast) artikull shkencor i botuar më 01 shkurt 1996 (sq) scientific article published on 01 February 1996 (en)
publication date	wds:Q71079802-F6F7D111-497C-4E11-90DD-B9708AC5BD55
publication date	1996-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71079802-91EA5591-4426-4B2E-A432-BB5A2F9C608F
language of work or name	English
author name string	wds:Q71079802-05468EF4-354C-486B-B50F-42154E00D80A wds:Q71079802-1A58C3EB-09DA-4FE0-9037-D7F1BA9FE92B wds:Q71079802-2E2EAC55-9969-4DC5-8B94-788169E73E87 wds:Q71079802-4FE8A74A-0B2C-4599-B13D-DDCC3EFE584A wds:Q71079802-7BA53659-A720-4B26-9F82-988D66AB9E6D wds:Q71079802-ADC584DB-394D-4C9B-A568-5DB9324407CE wds:Q71079802-BCEC9282-5945-4F3A-9409-01E0AAB26100 wds:Q71079802-C28C07BF-72FA-4F46-97DA-E0CBC01C9F15 wds:Q71079802-EAC5256C-7381-45B0-B43E-15FB2BF03592
author name string	M Fukuda T Ishida K Nishio M Oka N Saijo H Ogasawara F Kanzawa H Arioka K Bojanowski
rdfs:label	Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (en) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (nl) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (sq)
skos:prefLabel	Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (en) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (nl) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (sq)
name	Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (en) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (nl) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (sq)
title	wds:Q71079802-D629089B-54C9-4790-8BAA-93F7261D93D8
title	Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells (en)
page(s)	wds:Q71079802-14A7CFD3-A17E-44F8-8FA1-785F3B505EFA
page(s)	789-793
instance of	wds:Q71079802-DDBC0B63-58C9-4423-9A19-813B833CC325
instance of	scholarly article
main subject	wds:Q71079802-E0327923-011B-4940-8608-902F6C4ACB69 wds:Q71079802-EEB0948E-0C2E-41FB-97F7-6438B30F5957
main subject	lung cancer cisplatin
PubMed ID	wds:Q71079802-A5BBBE67-6475-4BFC-9D50-20B6D403388C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8631015
PubMed ID	8631015
published in	wds:Q71079802-BC6FC9F9-F841-47CA-8081-7A60EE366D7D
published in	Cancer Research
issue	wds:Q71079802-BCF5A20A-B037-48BF-AB55-8A38F2211EFC
volume	wds:Q71079802-9122C365-1107-4807-8C6D-F997ACDD7F68
issue	4
volume	56
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71079802
is cites work of	Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Researc New strategy for overcoming resistance to chemotherapy of ovarian cancer. A topoisomerase II inhibitor, NK109, induces DNA single- and double-strand breaks and apoptosis. Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells Enhanced anti-tumor effect of trastuzumab in combination with cisplatin Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes Progress in treatment of small-cell lung cancer: role of CPT-11. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours Topoisomerase I inhibitors and drug resistance Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC). Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer Phase I Study of Weekly Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer Highlights for ESMO 40: celebration review for lifetime achievement awards Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer The synergism between Belotecan and cisplatin in gastric cancer Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer
is cites work of	wds:Q33370887-F3E19D92-E38A-4157-B4B7-06CD3FC87C05 wds:Q38389182-8E0EACBC-7DA4-4FC4-910F-F1D8F6B850C5 wds:Q33858199-80A41298-C710-4E86-94F3-464A9839807F wds:Q35683541-1DF90598-5AA7-453A-B9F1-EB2025E9DD37 wds:Q36648316-0B283483-CF92-4D72-BF95-EFFE363726D7 wds:Q41857079-E334367A-F11C-4106-B5D8-519FBFFF3AE6 wds:Q33393176-6199EBDC-851A-47D5-9899-D7249AC53166 wds:Q35559881-27463FD5-1BEC-4EBC-8B9C-1237BA59D133 wds:Q44641300-C3D2C57E-B345-435C-B85B-40938AA5D92A wds:Q28075787-9D9A0198-1DC3-47AF-80AD-E26B14729381 wds:Q44010190-6322549F-4EA1-4CE1-BA37-386A891BAA0C wds:Q40028536-24F8CC2F-1D71-41C4-BD4D-2AD07E6F66BA wds:Q80800365-5949189C-89EE-4155-9A4C-A98956CB1564 wds:Q37165926-75C57C46-BA51-43C3-854F-B15E0CB23CA9 wds:Q37341744-036B67AE-88A6-4EFD-86C2-7123B321DC77 wds:Q41064010-DC5DFB80-61BE-48EE-ADC0-15D50927E24E wds:Q35608220-BA1B37D0-A5DD-4EAE-99F5-865B010F6490

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software